Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis
Medivir AB and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir's nucleotide polymerase inhibitor for hepatitis C,…
Read More...
Read More...